Clinical trial
A Single Dose, Two-Period, Two-Treatment Crossover Bioequivalency Study of 300 mg Lithium Carbonate Extended Release Tablets Under Fed Conditions
NCT00602394 is registered in ClinicalTrials.gov with Roxane Laboratories as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single Dose, Two-Period, Two-Treatment Crossover Bioequivalency Study of 300 mg Lithium Carbonate Extended Release Tablets Under Fed Conditions
- Lead sponsor
- Roxane Laboratories
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- May 31, 2003
- Completion date
- May 31, 2003
- Enrollment
- 30 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.